Literature DB >> 10422730

Galanin and NPY, two peptides with multiple putative roles in the nervous system.

T Hökfelt1, C Broberger, M Diez, Z Q Xu, T Shi, J Kopp, X Zhang, K Holmberg, M Landry, J Koistinaho.   

Abstract

In the present brief overview we summarize results from several studies focusing on two neuropeptides, galanin and neuropeptide Y (NPY) in discrete neuronal systems, where they coexist with classic transmitters. On the basis of studies in different animal models we propose that these peptides may be involved in regulation of certain CNS functions and that drugs acting on their receptors may be of use in new therapeutic strategies. At the spinal level galanin and NPY are regulated in DRG neurons by nerve injury and in dorsal horn neurons by inflammation. It is possible that this leads to attenuation of pain sensitivity. Moreover, both peptides may exert trophic effects, for example to enhance regeneration. In the hypothalamic arcuate nucleus NPY and its receptors are part of the feeding circuitry, and we suggest that derangement of these NPY neurons may at least in part underlay the lethal phenotype of anorectic mice, which die 22 days postnatally after showing decreased food intake and growth retardation. Expression of NPY and NPY receptors is changed in the hippocampus of mice comparatively early after prion inoculation, indicating that this peptide system is affected in this spongiform degenerative disease in a region of importance for learning and memory. Finally, galanin is co-localized with classic monoamine transmitters in two central systems, the dorsal raphe serotonin neurons and the locus coeruleus noradrenergic neurons. In both cases galanin causes hyperpolarization (at high concentrations) and prolongs monoamine-induced outward currents (at low concentrations), thus modulating activity in two systems of importance for many brain functions including mood regulation. It may therefore be interesting to analyse to what extent drugs affecting galaninergic transmission also may be efficient in the treatment of, for example, depression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10422730     DOI: 10.1055/s-2007-978748

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  14 in total

1.  Galanin transgenic mice display cognitive and neurochemical deficits characteristic of Alzheimer's disease.

Authors:  R A Steiner; J G Hohmann; A Holmes; C C Wrenn; G Cadd; A Juréus; D K Clifton; M Luo; M Gutshall; S Y Ma; E J Mufson; J N Crawley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

2.  Cell and gene therapies for refractory epilepsy.

Authors:  Detlev Boison
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

3.  Neuropeptide Y modulates effects of bradykinin and prostaglandin E2 on trigeminal nociceptors via activation of the Y1 and Y2 receptors.

Authors:  J L Gibbs; A Diogenes; K M Hargreaves
Journal:  Br J Pharmacol       Date:  2006-12-04       Impact factor: 8.739

4.  Neuropeptide Y has a protective role during murine retrovirus-induced neurological disease.

Authors:  Min Du; Niranjan B Butchi; Tyson Woods; Timothy W Morgan; Karin E Peterson
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

5.  Association of galanin haplotypes with alcoholism and anxiety in two ethnically distinct populations.

Authors:  I Belfer; H Hipp; C McKnight; C Evans; B Buzas; A Bollettino; B Albaugh; M Virkkunen; Q Yuan; M B Max; D Goldman; M A Enoch
Journal:  Mol Psychiatry       Date:  2006-03       Impact factor: 15.992

6.  Septal co-infusions of glucose with the benzodiazepine agonist chlordiazepoxide impair memory, but co-infusions of glucose with the opiate morphine do not.

Authors:  Desiree L Krebs-Kraft; Marise B Parent
Journal:  Physiol Behav       Date:  2009-12-22

7.  Leptin receptor neurons in the mouse hypothalamus are colocalized with the neuropeptide galanin and mediate anorexigenic leptin action.

Authors:  Amanda Laque; Yan Zhang; Sarah Gettys; Tu-Anh Nguyen; Kelly Bui; Christopher D Morrison; Heike Münzberg
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-03-12       Impact factor: 4.310

8.  Enhanced evoked excitatory transmitter release in experimental neuropathy requires descending facilitation.

Authors:  L R Gardell; T W Vanderah; S E Gardell; R Wang; M H Ossipov; J Lai; F Porreca
Journal:  J Neurosci       Date:  2003-09-10       Impact factor: 6.167

9.  Chronic low dose ovine corticotropin releasing factor or urocortin II into the rostral dorsal raphe alters exploratory behavior and serotonergic gene expression in specific subregions of the dorsal raphe.

Authors:  M S Clark; R A McDevitt; B J Hoplight; J F Neumaier
Journal:  Neuroscience       Date:  2007-04-30       Impact factor: 3.590

10.  Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests.

Authors:  Xiaoying Lu; Brendon Ross; Manuel Sanchez-Alavez; Eric P Zorrilla; Tamas Bartfai
Journal:  Neuropeptides       Date:  2008-06-12       Impact factor: 3.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.